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ABSTRACT
Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D.
The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D3) levels
before, directly after and 6 months after chemotherapy in breast cancer patients (n¼ 95),
and a comparison group of women (n¼ 52) not diagnosed with cancer. Changes in
25(OH)D3 levels over time were compared using linear mixed models adjusted for age and
season of blood sampling. Before start of chemotherapy, 25(OH)D3 levels were lower in
patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4)
compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P¼ 0.003). Directly after
chemotherapy, 25(OH)D3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5,
P¼ 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4,
P< 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D3 lev-
els remained stable throughout the study. Use of dietary supplements did not explain
recovery of 25(OH)D3 levels after chemotherapy. We reported lower 25(OH)D3 levels in
breast cancer patients, which decreased during chemotherapy, but recovered to levels
observed in women without cancer within 6 months after chemotherapy. Suboptimal
25(OH)D3 levels in the majority of the participants highlight the relevance of monitoring in
this vulnerable population.
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Introduction
Vitamin D, together with calcium, plays a critical role
in the regulation of bone health (1,2). Hence, subopti-
mal levels of vitamin D are associated with low bone
mineral density, osteoporosis and bone fractures,
which are commonly observed in breast cancer
patients (3–6). Moreover, emerging evidence suggests
that low levels of circulating vitamin D at the time of
breast cancer diagnosis are associated with poor clin-
ical outcomes, such as an increased risk of cancer
recurrence and mortality (7–11). These findings high-
light the relevance of a sufficient vitamin D status in
women with breast cancer.
Circulating levels of 25-hydroxyvitamin D
(25OHD) are considered a reliable biomarker for
vitamin D status (12). Although consensus about an
optimal vitamin D status has not been reached yet,
vitamin D deficiencies and insufficiencies are com-
monly defined as plasma or serum levels <50 nmol/L
(or <20 ng/mL) and 50–75 nmol/L (20–30 ng/mL),
respectively, whereas levels of 75 nmol/L (or 30 ng/
mL) are considered sufficient (13). Epidemiological
and clinical studies demonstrated that up to 96% of
newly diagnosed breast cancer patients had a vitamin
D deficiency (10,14–21). Most studies focusing on
clinical outcomes in breast cancer patients used a sin-
gle measurement of 25OHD at or around cancer diag-
nosis. It has, however, been hypothesized that
common systemic cancer treatments may interfere
with 25OHD levels, possibly through altered activities
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of drug-metabolizing enzymes, therapy-induced toxic-
ities, avoidance of sunlight and other personal or clin-
ical factors (22). Circulating levels of 25OHD have
been shown to decline after chemotherapy in breast
cancer patients in some (17,22–24), but not all studies
(25). To what extent these effects are persistent over
time is still unclear. Kim et al. demonstrated that
25OHD levels first declined, but recovered after the
end of chemotherapy in women with breast cancer
(24), whereas another study showed that 25OHD lev-
els were still lower 8 months after chemotherapy as
compared to pretreatment values (23). How potential
therapy-related changes in 25OHD levels in breast
cancer patients relate to fluctuations of 25OHD levels
in women without cancer remains unclear.
The aim of this study was to determine changes in
vitamin D levels by measuring serum 25-hydroxyvita-
min D3 25(OH)D3 levels before, directly after, and 6
months after chemotherapy in patients with stage
I–III breast cancer, and within a similar time frame in
a comparison group of women without cancer.
Subjects and Methods
Study Participants
This study was conducted as part of the COBRA
study, which is an observational multicenter study
among breast cancer patients receiving chemotherapy
and a comparison group of women not diagnosed
with cancer. Design of the study and recruitment of
the participants have been previously described in
detail (26). Briefly, 181 eligible patients with incident
stage I–IIIB breast cancer were recruited between May
2013 and November 2016 from 12 academic and per-
ipheral hospitals in the Netherlands prior to start of
neoadjuvant or adjuvant chemotherapy. The compari-
son group consisted of 180 women who had a similar
age (± 2 years) and who were recruited via the breast
cancer patients. All participants needed to be at least
18 years old and be able to communicate in Dutch.
Exclusion criteria were: a history of cancer except
basal cell carcinoma, previous treatment with chemo-
therapy, being pregnant or the intention to get preg-
nant during the study period, dementia or other
mental conditions that made it impossible to comply
with the study procedures. This study was approved
by the Medical Ethical Committee of Wageningen
University & Research (Protocol no. NL40666.081.12)
and all participants provided written informed consent
before enrollment. For the current study, circulating
25(OH)D3 levels were analyzed in all participants who
completed the study by the end of March 2016 (i.e.,
recruited up to April 2015) and who had blood sam-
ples available, resulting in a total of 441 samples from
147 participants (n¼ 95 patients and n¼ 52 women
from the comparison group). Recruitment of the
larger cohort continued after March 2016 (for other
research objectives) and therefore a proportion of the
original cohort has not been considered.
Blood Sampling and Vitamin D Measurements
Sample collection took place at three moments during
the study period, namely before start of chemotherapy
(T1), 1–3 weeks after the last cycle of chemotherapy
(T2), and 6 months after chemotherapy (T3). For
women in the comparison group, blood samples were
collected at similar time points namely at baseline (T1),
6 months after baseline (T2), and 12months after base-
line (T3). Nonfasted blood samples were collected in
8.5-mL serum tubes (Becton Dickinson B.V.). Serum
was collected after centrifugation and stored at –80 C
until analyses. All samples were shipped at the same
time and analyzed in the same laboratory (department
of Clinical Chemistry, Canisius Wilhelmina Hospital,
Nijmegen, the Netherlands). Levels of 25(OH)D3 were
measured using isotope-dilution liquid chromatography
(LC) tandem-mass spectrometry (MS/MS) (27). The
interassay coefficients of variation were as follows: 5.3%,
3.1% and 2.9% at 25(OH)D3 concentrations of 39.0, 92.5
and 127.0 nmol/L, respectively. The lower limit of quan-
tification (LLOQ) was 1 nmol/L. No samples showed
25(OH)D3 levels below the LLOQ. The current method
was also able to quantify levels of 25(OH)D2; however,
since 25(OH)D2 levels were below the LLOQ (2nmol/L)
for all except one patients, these values were not
considered for the current analyses. The vitamin D
status was defined as deficient (<50nmol/L), insufficient
(50–75nmol/L) or sufficient (75nmol/L) (13).
Data Collection
Demographic and general characteristics, including
age, height, smoking status (current, former, never),
educational level and menopausal status (pre- or post-
menopausal), were collected from a general question-
naire provided at baseline (T1). Educational level was
defined as low (primary school and lower vocational
education), medium (vocational education), or high
(higher professional education and university). The
validated Short QUestionnaire to ASsess Health
enhancing physical activity (SQUASH) was used to
calculate adherence to the Dutch physical activity
guideline (i.e., at least 30min moderate intense
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physical activity for a minimum of 5 days per week)
as described previously (28,29). Body weight was
determined by use of a dual-energy X-ray absorpti-
ometry (DEXA)-scanner in the hospitals at baseline
(T1). Body mass index (BMI) was calculated as body
weight divided by squared height (kg/m2). Use of diet-
ary supplements during the previous month was
reported as part of a food frequency questionnaire
provided at baseline (T1) and 6 months after chemo-
therapy (T3). Specific dietary supplements containing
vitamin D as well as multivitamins were considered
with regard to supplemental vitamin D intake. Most
multivitamins available in the Netherlands contain
vitamin D. The consistency of dietary supplement use
was determined based on intake at baseline (T1) and
6 months after the end of chemotherapy (patient
group) or 12months after baseline (comparison
group) (T3). Participants were categorized as consist-
ent users, consistent nonusers, participants who
started using supplements (‘starters’) and participants
who stopped using supplements (‘stoppers’) during
the study. In case of missing data on supplement use
at one of the indicated time points, consistency of
supplement use was classified as unknown.
Information on clinical characteristics, including adju-
vant or neoadjuvant chemotherapy and cancer stage,
was collected from the medical records.
Statistical Analysis
Population characteristics were presented as mean±
standard deviation (SD) or numbers and percentages.
Normality of the data was checked by visual inspection
of the QQ-plots. In case of data not following a normal
distribution, median and interquartile ranges (IQR) were
presented. Changes in 25(OH)D3 levels over time were
compared for patients and the comparison group using
a linear mixed model analysis with three time points
(T1–T3). Serum 25(OH)D3 levels were considered as
dependent variable in these analyses. Time, group and
their interaction (timegroup) were included as fixed
factors and subjects were defined as random factors in
the model. A random intercept was included to take
into account the individual variation in levels between
participants and the correlation between observations in
the same participant. The variance of components (VC)
was used as covariance structure. The final model was
adjusted for age at time of blood withdrawal (continu-
ous) and season of each individual blood withdrawal
(spring, summer, autumn, winter) as potential con-
founders, which were both included as fixed factors.
Results of the mixed model analyses were presented as
estimated marginal means and 95% confidence intervals
(95% CI), which were compared in a post-hoc analysis
with Sidak correction for multiple comparisons (30).
Explorative stratified analyses for timing of chemother-
apy (neoadjuvant versus adjuvant) and menopausal sta-
tus (pre-menopausal versus post-menopausal) were
conducted. Moreover, a sensitivity analysis excluding
the inconsistent users, i.e., those who reported changes
in dietary supplement containing vitamin D or with
incomplete data on supplement use, was performed.
IBM SPSS Statistics version 23 was used for all analyses
and the values of P< 0.05 were considered statistically
significant.
Results
Data on circulating 25(OH)D3 levels at all time points
were available for 95 breast cancer patients under-
going chemotherapy and 52 women without cancer
(Table 1). Age of the participants was on average 52.0
(SD 8.8, range 25–69) and 53.4 (SD 8.9, range 31–71)
years (women with and without breast cancer, respect-
ively). Menopausal status was comparable for the two
groups. Women with breast cancer tended to smoke
more often (19%) at the time of assessment as com-
pared to the women without cancer (8%). At baseline,
the majority of the participants adhered to the guide-
line for physical activity (60–63% at T1). Six months
after chemotherapy, a decline in adherence to this
guideline was observed for the patients with breast
cancer (48% versus 63% for women without cancer)
(Table 1).
The majority of the patients (n¼ 62, 65%) received
chemotherapy in the adjuvant setting. A regimen with
docetaxel, doxorubicin and cyclophosphamide (TAC)
or with 5-fluorouracil, epirubicin, cyclophosphamide
and docetaxel (FEC/DOC) was most commonly pre-
scribed (37% and 33%, respectively). The median time
between breast cancer diagnosis and start of chemo-
therapy was 25 days (IQR 19–37) for patients receiving
neoadjuvant chemotherapy and 91 days (IQR 71–111)
for patients receiving adjuvant chemotherapy. The
participants of the current study were representative
for the total study population of the COBRA study
with regard to the studied variables (n¼ 181 patients
and n¼ 180 women without cancer, data not shown).
In this study, 79% of the women with breast cancer
showed an insufficient vitamin D status (<75 nmol/L)
before the start of chemotherapy and 50% of the
women even showed a vitamin D deficiency
(<50 nmol/L). In the comparison group, insufficient
and deficient levels of 25(OH)D3 at start of the study
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were found in 63% and 31% of the women, respect-
ively (Fig. 1). It should be noted, however, that these
descriptive data did not take the season of blood sam-
pling into account, which slightly differed between the
groups. Therefore, we continued with linear mixed
model analyses to confirm these findings while con-
sidering season of blood sampling as well as age at
time of blood withdrawal.
The estimated marginal means (95% CI) retrieved
from the linear mixed model analysis are presented in
Fig. 2. A statistically significant interaction for time
and participant group was found (P¼ 0.001). Post-hoc
analyses demonstrated that before start of chemother-
apy, 25(OH)D3 levels were lower in the patients with
breast cancer (55.8, 95% CI 51.2–60.4 nmol/L) as com-
pared to the comparison group (67.2, 95% CI
61.1–73.3 nmol/L) (P¼ 0.003). Also directly after
chemotherapy, patients had lower 25(OH)D3 levels
(50.7, 95% CI 46.1–55.2 nmol/L) as compared to
women without cancer (68.7, 95% CI 62.6–74.9 nmol/
L) (P< 0.001), whereas 6 months after chemotherapy
these differences between the groups disappeared
Table 1. Description of the study population.
Breast cancer patient
group (n¼ 95)
Comparison
group (n¼ 52) P-valueg
General characteristics
Age (years), mean (SD) 52.0 (8.8) 53.4 (8.9) 0.355
Body mass index (kg/m2), median (IQR)a 25.2 (22.5–27.9) 23.3 (21.7–27.1) 0.075
Smoking status, n (%)b 0.048
Current 18 (19%) 4 (8%)
Former 40 (42%) 18 (35%)
Never 35 (37%) 29 (56%)
Menopausal status, n (%)b 0.988
Pre-menopausal 53 (56%) 29 (56%)
Post-menopausal 40 (42%) 22 (42%)
Educational level, n (%) 0.154
Low 7 (7%) 3 (6%)
Medium 36 (38%) 13 (25%)
High 49 (52%) 36 (69%)
Unknown 3 (3%) –
Use of dietary supplements containing vitamin D at start of the study (T1)c (yes), n (%) 30 (32%) 16 (31%) 0.802
Season of drawing first blood sample (T1), n (%) 0.927
Spring (21 March–21 May) 21 (22%) 11 (21%)
Summer (21 June–21 August) 16 (17%) 11 (21%)
Autumn (21 September–21 November) 18 (19%) 10 (19%)
Winter (21 December–21 February) 40 (42%) 20 (39%)
Season of drawing last blood sample (T3), n (%) 0.023
Spring (21 March–21 May) 17 (18%) 8 (15%)
Summer (21 June–21 August) 12 (13%) 14 (27%)
Autumn (21 September–21 November) 29 (31%) 6 (12%)
Winter (21 December–21 February) 37 (39%) 24 (46%)
Adherence to recommendation for physical activity (T1)d (yes), n (%) 57 (60%) 33 (64%) 0.686
Adherence to recommendation for physical activity (T3)e (yes), n (%) 46 (48%) 33 (64%) 0.075
Clinical characteristics
Tumor stage, n (%) –
I 32 (34%) NA
II 52 (55%) NA
III 11 (12%) NA
Timing of chemotherapy, n (%) –
Neoadjuvant 33 (35%) NA
Adjuvant 62 (65%) NA
Type of chemotherapy, n (%) –
TAC 35 (37%) NA
FEC/DOC 31 (33%) NA
ACPT 11 (12%) NA
AC/DOC/T 6 (6%) NA
Other 12 (13%) NA
Circulating vitamin D levels
Serum 25OHD at baseline (T1) (nmol/L), mean (SD) 54.1 (22.8) 66.1 (23.5) 0.003
Serum 25OHD directly after CTx (T2)f (nmol/L), mean (SD) 52.4 (21.4) 70.5 (25.5) <0.001
Serum 25OHD 6 months after CTx (T3)f (nmol/L), mean (SD) 64.9 (24.5) 69.0 (21.2) 0.304
Data are presented as mean (standard deviation), median (interquartile range) or numbers (percentage). aData missing for one patient.bData missing for
one participant from the comparison group and two patients. cMultivitamins or specific dietary supplements containing vitamin D. Data missing for two
participants from the comparison group and seven patients. dDutch recommendations for physical activity referring to  150min moderate intensive
physical activity per week. Data missing for one participant from the comparison group and two patients. eData missing for three participants from the
comparison group and six patients. fComparable time points for women without cancer refer to 6 months (T2) and 12 months after baseline (T3).
gCalculated through Mann–Whitney U tests, Student’s t-tests or chi-square tests. CTx, chemotherapy; TAC, docetaxel, doxorubicin, cyclophosphamide;
FEC/DOC, 5-fluorouracil, epirubicin, cyclophosphamide and docetaxel; ACPT, doxorubicin, cyclophosphamide, paclitaxel and trastuzumab; AC/DOC/T,
doxorubicin, cyclophosphamide, docetaxel and trastuzumab; NA, not applicable.
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(66.7, 95% CI 62.1–71.2 and 69.8, 95% CI
63.6–76.0 nmol/L, respectively, P¼ 0.421) (Fig. 2A).
Directly after chemotherapy, 25(OH)D3 levels were on
average 5.1 (95% CI –10.7–0.5) nmol/L lower as com-
pared to pre-chemotherapy values (T2 versus T1,
P¼ 0.082) in the patients. In this group, 25(OH)D3
levels increased again 6 months after chemotherapy
(T3 versus T2¼ 16.0, 95% CI 10.4–21.7 nmol/L,
P< 0.001) and ended up higher as compared to pre-
chemotherapy values (T3 versus T1¼ 10.9, 95% CI
5.5–16.4 nmol/L, P< 0.001), whereas 25(OH)D3 levels
of the women without cancer did not statistically sig-
nificantly change over time (Table 2). Stratified analy-
ses for patients receiving neoadjuvant versus adjuvant
chemotherapy or for pre-menopausal versus post-
menopausal participants showed similar find-
ings (Fig. 2B–E).
Before start of chemotherapy (T1), 32% (n¼ 30) of
the patients and 31% (n¼ 16) of the women without
cancer reported use of dietary supplements containing
vitamin D in the past month. Six months after
chemotherapy (T3), this percentage increased to 47%
(n¼ 45) of the patients and 29% (n¼ 15) of the
women without cancer. Consistent vitamin D supple-
ment use was reported in 23% (n¼ 22) of the patients
and 23% (n¼ 12) of the women without cancer (Fig.
3). Throughout the study, 21% (n¼ 20) of the patients
reported that they started taking dietary supplements
with vitamin D, whereas 6% (n¼ 6) patients stopped
using supplements with vitamin D. For the group of
women without cancer, 6% (n¼ 3) started and 6%
(n¼ 3) stopped use of dietary supplements with vita-
min D. Given the dynamics of supplement use in this
study population, we explored to what extent changes
in supplement use may have accounted for the
observed changes in 25(OH)D3 levels. A sensitivity
analyses excluding participants who reported changes
in dietary supplement use (n¼ 26 breast cancer
patients and n¼ 6 women without cancer) or with
unavailable data on supplement use (n¼ 13 breast
cancer patients and n¼ 6 women without cancer)
showed similar findings (Table 2). Thus, also for this
population of consistent users and nonusers of dietary
supplements containing vitamin D, 25(OH)D3 levels
Figure 1. Percentage of participants with a sufficient, insufficient or deficient vitamin D status. Vitamin D status in breast cancer
patients (n¼ 95) and women without cancer (n¼ 52) according to the time of sample collection. Baseline samples were collected
before start of chemotherapy (CTx) for patients with breast cancer.
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declined directly after chemotherapy and increased
again 6 months after chemotherapy in the breast can-
cer patients (n¼ 56), but remained stable in the
women without cancer (n¼ 40) (Table 2).
Discussion
The aim of this study was to assess changes in circu-
lating 25(OH)D3 levels throughout the course of
chemotherapy in patients with stage I–III breast can-
cer as compared to a group of women without cancer.
We have shown that suboptimal levels of 25(OH)D3
are common among breast cancer patients as well as
women without cancer. Importantly, 25(OH)D3 levels
before start of chemotherapy were lower in patients
with breast cancer as compared to women without
cancer and further declined during chemotherapy.
The proportion of patients with a sufficient vitamin D
status (15%) became alarmingly small directly after
chemotherapy. Six months after the end of chemo-
therapy, 25(OH)D3 levels in breast cancer patients
returned to levels observed in the comparison group
independent of the season of blood sampling or
changes in dietary supplement use. Circulating levels
of 25(OH)D3 remained stable throughout the study in
women without cancer.
Figure 2. Changes in circulating 25(OH)D3 levels. Estimated marginal means (95% confidence intervals) of the circulating 25(OH)D3
levels throughout the course of chemotherapy (CTx) in patients with breast cancer and at comparable time points for women
from the comparison group based on a linear mixed model analysis. The analyses were adjusted for age and season of each blood
withdrawal. aStatistically significant interaction for timegroup in the linear mixed model analysis. Indicates a statistically signifi-
cant difference (Sidak-adjusted P< 0.05) for the comparison between patients and women without cancer identified through a
pairwise post-hoc analysis. Indicates a statistically significant change over time in the patients with breast cancer (Sidak-adjusted
P< 0.05). A] All patients with breast cancer (n¼ 95) and women without cancer (n¼ 52), B] Patients receiving adjuvant chemo-
therapy (n¼ 62) and women without cancer (n¼ 52), C] Patients receiving neoadjuvant chemotherapy (n¼ 33) and women with-
out cancer (n¼ 52), D] Pre-menopausal patients (n¼ 53) and women without cancer (n¼ 29), E] Post-menopausal patients
(n¼ 40) and women without cancer (n¼ 22).
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Vitamin D deficiencies are commonly reported in
patients with breast cancer (10,14–21). Also in our
study, half of the breast cancer patients (50%) had a
vitamin D deficiency at start of the study. Various,
but not all, studies agreed that higher vitamin D levels
were associated with better breast cancer outcomes
and survival (7–11). Most of these studies assessed
serum 25OHD levels up to one year prior to or
shortly after breast cancer diagnosis. It should be
noted that various factors, including changes in diet
and lifestyle after cancer diagnosis and cancer treat-
ments may impact circulating 25OHD levels. This
raises the clinically relevant question whether 25OHD
levels are subjective to changes after cancer diagnosis.
Only few studies have examined 25OHD levels
throughout the course of chemotherapy in breast can-
cer patients. A small study among nine women with
breast cancer suggested that serum 25OHD levels
remained stable during chemotherapy with FEC (25).
Others, however, have reported an increased preva-
lence of vitamin D deficiencies after neoadjuvant
chemotherapy among 77 women with locally
advanced breast cancer (44% before treatment versus
73% around the last cycle) (17). Similarly, 73 patients
Table 2. Changes in 25OHD levels over time.
Overall analyses
Breast cancer patient group (n5 95) Comparison group (n5 52)
Estimated mean change (nmol/L) 95% confidence interval P-valuea Estimated mean
change (nmol/L)
95% confidence
interval
P-valuea
T2–T1 –5.1 –10.7 ; 0.5 0.082 1.5 –5.8 ; 8.9 0.945
T3–T2 16.0 10.4 ; 21.7 <0.001 1.1 –6.3 ; 8.5 0.978
Stratified analysis for menopausal status: pre-menopausalb
Breast cancer patient group (n5 53) Comparison group (n5 29)
T2–T1 –6.8 –14.9 ; 1.3 0.125 –1.2 –11.7 ; 9.3 0.990
T3–T2 18.3 10.1 ; 26.6 <0.001 1.3 –9.2 ; 11.9 0.987
Stratified analysis for menopausal status: post-menopausalb
Breast cancer patient group (n5 40) Comparison group (n5 22)
T2–T1 –4.5 –12.1 ; 3.0 0.386 6.4 –4.2 ; 17.1 0.377
T3–T2 14.3 6.5 ; 22.0 <0.001 0.3 –10.4 ; 10.9 1.000
Sensitivity analysisc
Breast cancer patient group (n5 56) Comparison group (n5 40)
T2–T1 –7.9 –13.8 ; -2.1 0.004 0.8 –6.0 ; 7.6 0.987
T3–T2 12.8 6.9 ; 18.6 <0.001 0.7 –6.2 ; 7.5 0.994
Estimated mean changes in 25(OH)D3 levels over time calculated using a linear mixed model analysis adjusted for age and season of blood withdrawal.
Time points indicate T1: before start of chemotherapy, T2: directly after chemotherapy and T3: 6 months after chemotherapy for patients and T1: base-
line, T2: 6 months after baseline and T3: 12months after chemotherapy for women without cancer in the comparison group. aAdjusted for multiple
comparisons using the Sidak procedure in the pairwise post-hoc analysis. bAnalyses stratified for menopausal status. Menopausal status unknown for
two patients and one participant from the comparison group. cSensitivity analysis excluding participants reporting inconsistent use of dietary
supplements (starters and stoppers) and the participants for whom it is unknown whether they used dietary supplements at the indicated time points.
Figure 3. Use of dietary supplements containing vitamin D. Dietary supplements with vitamin D as well as multivitamins contain-
ing vitamin D were considered. Use of these supplements was reported by the participants at start of the study (T1) and 6 months
after the end of chemotherapy for patients (i.e. 12months after start of the study for the comparison group) (T3). Consistency is
reflecting use or nonuse of these supplements at the indicated time points, whereas inconsistency refers to changes in dietary sup-
plement use (i.e., starting of stopping use of dietary supplements containing vitamin D). A] Patients with breast cancer (n¼ 95), B]
Women without cancer from the comparison group (n¼ 52).
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with breast cancer from Iran showed declined levels
of serum 25(OH)D3 (minus 13%) 8 months after the
end of adjuvant chemotherapy as compared to pre-
chemotherapy values (23). Charehbili et al. have
studied the effects of neoadjuvant chemotherapy, with
or without the bisphosphonate zoledronic acid, on
25(OH)D3 levels in 73 stage II–III breast cancer
patients with HER2-negative tumors participating in
the NEOZOTAC trial (22). For patients receiving neo-
adjuvant TAC without zoledronic acid and vitamin D/
calcium (n¼ 34), the decline in 25(OH)D3 levels was
–16 nmol/L (SD 25.2) (22). It should be noted, how-
ever, that these analyses were not adjusted for season
of blood sampling. In our study, an adjusted decrease
of 5 nmol/L (95% CI –10.7–0.5) was found 1–3 weeks
after the last cycle of chemotherapy compared to pre-
chemotherapy values (P¼ 0.082). Hence, our findings
are consistent with the results of the NEOZOTAC
trial (22), which was conducted among a comparable
group of breast cancer patients in the Netherlands.
However, the magnitude of the decrease in 25(OH)D3
levels directly after chemotherapy was modest in our
study compared to the NEOZOTAC trial. Potential
explanations for this discrepancy may be the timing of
blood sampling which was conducted before the last
cycle of chemotherapy in the NEOZOTAC trial and
1–3 weeks after chemotherapy in our study. Possibly,
levels of 25(OH)D3 already started to recover shortly
after chemotherapy. Also baseline 25(OH)D3 levels,
which were higher for the NEOZOTAC participants
as compared to our population (deficiency in 38%
and 50% of the patients, respectively), or different
chemotherapeutic settings (neoadjuvant TAC and
various neoadjuvant or adjuvant regimens, respect-
ively) may explain these findings.
Based on our data, we also had the opportunity to
study changes in 25(OH)D3 levels over a prolonged
time period and to compare trajectories in 25(OH)D3
levels with those of women without cancer.
Interestingly, 6 months after the end of chemotherapy,
serum 25(OH)D3 levels returned to values observed in
women without cancer. As a consequence, also the
prevalence of vitamin D deficiencies among the breast
cancer patients decreased from 50% before start of
chemotherapy to 32% 6 months after the end of
chemotherapy. These results are in agreement with
the findings of Kim et al. who demonstrated that
serum 25OHD levels in 93 Korean women with breast
cancer receiving adjuvant chemotherapy decreased
during the first 6 months after diagnosis, but recov-
ered 12months after diagnosis (24). We have now
added further evidence suggesting that serum
25(OH)D3 levels even returned to 25(OH)D3 levels
observed in women without cancer. Various mecha-
nisms may explain the recovery of 25(OH)D3 levels 6
months after the end of chemotherapy. Our first
thought was that patients, who may become more
health conscious during and after cancer treatment
(31), could have changed their use of dietary supple-
ments containing vitamin D. Dietary supplements
containing vitamin D substantially contribute to
25(OH)D3 levels (32,33). At the start of our study,
32% of the patients (and 31% of the women without
cancer) reported use of dietary supplements contain-
ing vitamin D in the past month. At the end of the
study, the percentage of patients who reported use of
dietary supplements containing vitamin D in the pre-
vious month increased to 47%, which is in line with
previous studies showing that dietary supplement use
is common among cancer survivors in general, and
breast cancer survivors in particular (34–36).
However, our sensitivity analysis for which the partici-
pants who changed their use of dietary supplements
containing vitamin D were excluded, showed similar
results and provided compelling evidence that changes
in dietary supplement use were not primarily respon-
sible for the observed increases in serum 25(OH)D3
levels after chemotherapy.
Alternative explanations for the observed recovery
of 25(OH)D3 levels may refer to other behavioral
changes or biological aspects. Potential diet and life-
style behaviors that the patients adopted after cancer
diagnosis (37,38), such as changed dietary habits,
increased physical activity, more outdoor activities
and sunlight exposure, may have contributed to
increased 25(OH)D3 levels. In the current study, data
on sun exposure were not available. Our data on
adherence to the national recommendations for phys-
ical activity did not provide evidence that women
with breast cancer increased their physical activity
after the end of chemotherapy, although changes in
type of activities or outdoor behaviors cannot be
excluded. From a tumor biology point of view,
removal of the tumor by surgical resection and
chemotherapy may have also resulted in recovery of
circulating 25(OH)D3 levels. Previous studies sug-
gested that regulation of the vitamin D pathway may
be altered in breast cancer cells (39,40). For example,
more stable CYP24 mRNA profiles, responsible for
clearing of the active metabolite 1,25(OH)2D, were
found in human breast cancer cells as compared to
normal human mammary epithelial cells (41). Also
(epigenetic) deregulation and altered expression levels
of the vitamin D receptor (VDR) gene during breast
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carcinogenesis have been described (39,40,42,43).
Moreover, exogenous 25OHD exposure resulted in
local accumulation of 25OHD and the active metabol-
ite 1,25(OH)2D in tumor tissue of a breast cancer
mouse model (44). Altogether, these findings may
point toward altered metabolism of vitamin D during
carcinogenesis and potentially increased demands of
breast cancer cells. This hypothesis remains, however,
speculative and needs to be confirmed, since the exact
role of uptake, storage and metabolism of vitamin D
in breast cancer tissue is not fully understood (39)
and cannot be addressed in our study. Also alternative
mechanisms or personal or clinical factors determin-
ing vitamin D levels in patients receiving chemother-
apy, need to be explored in future studies.
Potential limitations of our study include the rela-
tively small sample size and our heterogeneous popu-
lation in terms of tumor characteristics, timing of
treatment, and cytotoxic regimens. This can, however,
also be considered a strength, since the population of
breast cancer patients in the Netherlands is character-
ized by heterogeneity as well. It should be recognized
that patients and women from the comparison group
slightly differed with regard to some characteristics
(e.g., smoking status, BMI and physical activity).
These differences may have potentially impacted com-
parisons between the groups, but are not likely to
affect analyses dedicated to changes in 25(OH)D3 lev-
els within the respective groups. Strengths of our
study are the measurements of 25(OH)D3 levels at
multiple time points after diagnosis and the assess-
ment of dietary supplement use throughout the course
of cancer therapy. Moreover, the consideration of a
comparison group of women without cancer can be
considered a major strength of the current study.
In conclusion, our results confirmed that vitamin
D deficiencies are common among Dutch patients
with breast cancer. After the end of chemotherapy,
circulating 25(OH)D3 levels recovered and within 6
months even returned to levels observed in women
without cancer. However, suboptimal levels of vitamin
D were still observed in the majority of the women
participating in this study, which may have important
clinical implications. This finding underpins the rele-
vance of awareness and potentially careful monitoring
of vitamin D levels in this vulnerable population of
women approaching menopausal age with an
increased risk of declined bone health. In addition,
our findings may provide interesting leads for further
studies dedicated to the hypothesis that low serum
25(OH)D3 levels are, at least partly, resulting from
breast tumor biology.
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